Photo by nci from unsplash
&NA; Patients who receive a diagnosis of metastatic castration‐sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis,… Click to show full abstract
&NA; Patients who receive a diagnosis of metastatic castration‐sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.
Keywords:
castration sensitive;
prostate cancer;
metastatic castration;
sensitive prostate;
cancer
Journal Title: Clinical Genitourinary Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Genitourinary Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!